Skip to main content
Crispr Therapeutics AGSEC 10-Q

Collaboration revenue was $12.3 million from Vertex under the 2015 Collaboration Agreement

What happened

Collaboration revenue recognized for the three months ended September 30, 2026 was $12.3 million out of $12.7 million in total revenue, primarily relating to previously deferred revenue from Vertex. This high revenue reliance on a single partner may drive...

Source

Extracted by Autobound

From the Signal API record
Signal
SEC 10-Q

What this signalsFilings often name leadership changes, deals and spending plans.

Filed
Nov 2, 2026

More SEC 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figurepreviously deferred collaboration revenue recognized under an amendment to the 2015 Collaboration Agreement with Vertex
$12.3M

Details

CIK
1674416
Accession number
0001193125-26-443665
Timeframe
Current quarter
Quarter
Q3
Filing year
2026
Fiscal year end
09/30
Period end date
Sep 30, 2026
Why it matters
Diversification strategy
Signal category
Market

Extraction

Confidence
High
Relevance
75%
Sentiment
Neutral
Detected
Nov 3, 2026
signal_type
sec-10q
signal_subtype
customerConcentration

Use this data

Get every SEC 10-Q signal for Crispr Therapeutics AG and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Crispr Therapeutics AG this week?”

  2. Send it to your own tools

    The Signal API returns SEC 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/5cd815b2-71dd-423b-b54a-b088f2826bcc returns this record as JSON. POST /v1/companies/enrich returns every signal for crisprtx.com.

{
  "signal_id": "5cd815b2-71dd-423b-b54a-b088f2826bcc",
  "signal_type": "sec-10q",
  "signal_subtype": "customerConcentration",
  "detected_at": "2026-11-03T07:08:48.553+00:00",
  "company": {
    "name": "Crispr Therapeutics AG",
    "domain": "crisprtx.com"
  },
  "data": {
    "detail": "Collaboration revenue recognized for the three months ended September 30, 2026 was $12.3 million out of $12.7 million in total revenue, primarily relating to previously deferred revenue from Vertex. This high revenue reliance on a single partner may drive interest in commercial diversification and alternative platform monetization solutions.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "previously deferred collaboration revenue recognized under an amendment to the 2015 Collaboration Agreement with Vertex",
      "dollar_millions": 12.3
    },
    "quarter": "Q3",
    "summary": "Collaboration revenue was $12.3 million from Vertex under the 2015 Collaboration Agreement",
    "relevance": 0.75,
    "sentiment": "neutral",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1674416/000119312526443665/crsp-20260930.htm",
    "filing_date": "2026-11-02",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "09/30",
    "period_end_date": "2026-09-30",
    "sales_relevance": "Diversification strategy",
    "signal_category": "market"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.